Giulio Porcedda

Dr. Giulio Porcedda


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2019 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
GPGiulio Porcedda
Giulio Porcedda
ABAlice Brambilla
Alice Brambilla
SFSilvia Favilli
Silvia Favilli
GSGaia Spaziani
Gaia Spaziani
GMGiuseppe Mascia
Giuseppe Mascia
MGMarzia Giaccardi
Marzia Giaccardi

20 July 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
GSGaia Spaziani
Gaia Spaziani
FGFrancesca Girolami
Francesca Girolami
LALuigi Arcieri
Luigi Arcieri
GCGiovanni Battista Calabri
Giovanni Battista Calabri
GPGiulio Porcedda
Giulio Porcedda
SFSilvia Favilli
Silvia Favilli
Bicuspid aortic valve (BAV) is the most common congenital heart defect. Prevalence of isolated BAV in the general pediatric population is about 0.8%, but it has been reported to be as high as 85% in patients with aortic coarctation. A genetic basis has been recognized, with great heterogeneity. Standard BAV terminology, recently proposed on the basis of morpho-functional assessment by transthoracic echocardiography, may be applied also to the pediatric population. Apart from neonatal stenotic BAV, progression of valve dysfunction and/or of the associated aortic dilation seems to be slow during pediatric age and complications are reported to be much rarer in comparison with adults. When required, because of severe BAV dysfunction, surgery is most often the therapeutic choice; however, the ideal initial approach to treat severe aortic stenosis in children or adolescents is not completely defined yet, and a percutaneous approach may be considered in selected cases as a palliative option in order to postpone surgery. A comprehensive and tailored evaluation is needed to define the right intervals for cardiologic evaluation, indications for sport activity and the right timing for intervention.

19 April 2017 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MHMay El Hachem
May El Hachem
FGFrancesco Gesualdo
Francesco Gesualdo
ADAndrea Diociaiuti
Andrea Diociaiuti
IBIrene Berti
Irene Berti
NVNadia Vercellino
Nadia Vercellino
PDPietro Dalmonte
Pietro Dalmonte
Despite not being licensed for the treatment of infantile hemangiomas (IH) in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications. The objective of the present study was to review the experience of 8 Italian pediatric and dermatologic centers regarding propranolol treatment for IH started before 5 weeks or after 5 months of age. We retrospectively reviewed the records of patients followed up for IH, on propranolol treatment started before 5 weeks or after 5 months of age, and collected information on sociodemographic data, treatment indications, IH involution, IH relapse, and treatment side effects. A total of 343 patients were enrolled; 15 were started on propranolol before 5 weeks (group 1), 328 were started after 5 months of age (group 2). The most frequent indications were permanent aesthetical disfigurement (91.8%) and function threatening complications (42.6%). In most cases, the treatment was effective. The involution was partial in 67.7% of patients. In 11.8% of cases a relapse was observed. No relapse was observed in group 1. Treatment complications were reported in 15.8% of children, most frequently sleep disorders (6.6%), followed by irritability (5.1%) and diarrhea (2.2%). Only a case of mild constipation was observed in group 1. The safety and effectiveness profile of propranolol in infants younger than 5 weeks or older than 5 months may be acceptable. Taking in account propranolol's potential in preventing severe complications, further studies should assess the acceptability of propranolol treatment, especially in the <5-week age group .

24 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FGFrancesca Girolami
Francesca Girolami
AGAlessia Gozzini
Alessia Gozzini
Eszter Dalma PalinkasEszter Dalma Palinkas
Eszter Dalma Palinkas
ABAdelaide Ballerini
Adelaide Ballerini
ATAlessia Tomberli
Alessia Tomberli
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Genetic counselling and genetic testing in hypertrophic cardiomyopathy (HCM) represent an integral part of the diagnostic algorithm to confirm the diagnosis, distinguish it from phenocopies, and suggest tailored therapeutic intervention strategies. Additionally, they enable cascade genetic testing in the family. With the implementation of Next Generation Sequencing technologies (NGS), the interpretation of genetic data has become more complex. In this regard, cardiologists play a central role, aiding geneticists to correctly evaluate the pathogenicity of the identified genetic alterations. In the ideal setting, geneticists and cardiologists must work side by side to diagnose HCM as well as convey the correct information to patients in response to their many questions and concerns. After a brief overview of the role of genetics in the diagnosis of HCM, we present and discuss the frequently asked questions by HCM patients throughout our 20-year genetic counselling experience. Appropriate communication between the team and the families is key to the goal of delivering the full potential of genetic testing to our patients.

Verified
Journal Article
Open access
PDF file
Massimo Stefano SilvettiMassimo Stefano Silvetti
Massimo Stefano Silvetti
CDColonna Diego
Colonna Diego
FGFulvio Gabbarini
Fulvio Gabbarini
GPGiulio Porcedda
Giulio Porcedda
ARAlessandro Rimini
Alessandro Rimini
LLLoira Leoni
Loira Leoni
Guidelines are important tools to guide the diagnosis and treatment of patients to improve the decision-making process of health professionals. They are periodically updated according to new evidence. Four new Guidelines in 2021, 2022 and 2023 referred to pediatric pacing and defibrillation. There are some relevant changes in permanent pacing. In patients with atrioventricular block, the heart rate limit in which pacemaker implantation is recommended was decreased to reduce too-early device implantation. However, it was underlined that the heart rate criterion is not absolute, as signs or symptoms of hemodynamically not tolerated bradycardia may even occur at higher rates. In sinus node dysfunction, symptomatic bradycardia is the most relevant recommendation for pacing. Physiological pacing is increasingly used and recommended when the amount of ventricular pacing is presumed to be high. New recommendations suggest that loop recorders may guide the management of inherited arrhythmia syndromes and may be useful for severe but not frequent palpitations. Regarding defibrillator implantation, the main changes are in primary prevention recommendations. In hypertrophic cardiomyopathy, pediatric risk calculators have been included in the Guidelines. In dilated cardiomyopathy, due to the rarity of sudden cardiac death in pediatric age, low ejection fraction criteria were demoted to class II. In long QT syndrome, new criteria included severely prolonged QTc with different limits according to genotype, and some specific mutations. In arrhythmogenic cardiomyopathy, hemodynamically tolerated ventricular tachycardia and arrhythmic syncope were downgraded to class II recommendation. In conclusion, these new Guidelines aim to assess all aspects of cardiac implantable electronic devices and improve treatment strategies.

16 November 2024 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
SGSimone Gasparini
Simone Gasparini
SSSara Senese
Sara Senese
ESErica Scuma
Erica Scuma
FPFabiana Parodi
Fabiana Parodi
AGArianna Gianfredi
Arianna Gianfredi
TPTiziana Pisano
Tiziana Pisano